Introduction
Pregnane X receptor [PXR, also known as steroid X receptor (SXR)], a member of the nuclear receptor superfamily predominantly expressed in the liver and intestine, is known as a xenosensor, playing a key role in response to xenochemical stimuli. Upon activation, PXR forms a heterodimer with retinoid X receptor alpha (RXRα and recruits co-activators instead of co-repressors, resulting in the enhanced expression of various drug-metabolizing enzymes and transporters. These include both cytochrome P450 3A4 (CYP3A4) and multidrug resistance protein 1 (MDR1), which contribute to the metabolism of more than half of the prescribed medicines (Chibueze et al., 2011; Chen et al. 2012) . The target genes of PXR have specific responsive elements in their promoter regions. In the CYP3A4 proximal promoter region, an everted repeat of half hexamers separated by six nucleotides (ER6) was identified as a proximal PXR responsive element (prER6; -169/-152) (Blumberg et al., 1998) .
Furthermore, the distal enhancer module in the CYP3A4 promoter (xenobiotic responsive enhancer module, XREM; -7.8/-7.2 kb) contains two additional PXR responsive elements, direct repeat 3 (DR3) nuclear receptor-binding element 1 (dNR1, -7733/-7719) (Goodwin et al., 1999) , and DR4-type PXR responsive element (eNR3A4, -7618/-7558) (Toriyabe et al., 2009 ).
Recently, PXR has received renewed attention as a molecular target for the treatment of 
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6 inflammatory bowel disease (Shah et al., 2007; Cheng et al., 2012) , dyslipidemia (Gao and Xie, 2012) , and cholestatic liver disease (Kakizaki et al., 2011) . For example, recent clinical trials with the antibiotic rifaximin, a PXR agonist in the gastrointestinal system, revealed its potential therapeutic value in the treatment of intestinal inflammation in humans (Cheng et al., 2012) .
A large number of chemicals have been reported to activate PXR. These compounds have large chemical structural diversity, including steroids, xenobiotics, and natural products such as clinical drugs and medicinal herb extracts. However, most of the known PXR agonists are also ligands of the closely related xenosensing nuclear receptor, constitutive androstane receptor (CAR) and our knowledge on selective PXR agonists are quite limited. Only a few of compounds, exemplified by rifampicin and ginkgolides A-C (Lau et al. 2012) , have been known as selective PXR agonists but not that of CAR.
Pepper, the fruits of Piper nigrum L. (Piperaceae), is one of the most well-known spices in the world. The biological activities of pepper, such as stimulation of the central nervous system, analgesic, and antipyretic activities were reported due to its major constituents: ilepcimide (10) and piperine (11) (Wei et al. 2004a) . The edible roots of P. nigrum were traditionally used in soup to promote sleep in Hainan island, where is the largest region for planting of P. nigrum in China. Phytochemical investigations of the roots of P. nigrum disclosed cyclohexane-type amide alkaloids as the typical constituents, but their biological activity are yet unclear (Wei et During our investigation of discovery of novel ligands of nuclear receptors, in the present study, we reported the identification of nigramide C (NigC), a naturally occurring cyclohexane-type amide alkaloid from the root of Piper nigrum, as a novel PXR agonist. The role of NigC in the transcriptional activity of PXR was examined.
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Materials and Methods

Chemicals
The cyclohexene-type amide alkaloids (1-9, 12, and 13) and related monomeric alkaloids ilepcimide (10) and piperine (11) used in the present study are natural compounds (1 or NigC, 3 or nigramide J, 5, 6, 8, 10, and 12) isolated from the roots of Piper nigrum, or semi-synthetic compounds (2, 4, 7, 9, 11, and 13) (Wei et al., 2004a (Wei et al., , 2004b (Wei et al., , 2005 . The purity of these compounds (> 98%) was determined by high-performance liquid chromatography and NMR analyses.
Plasmid construction
The expression plasmids for hPXR/ligand binding domain (LBD) fused with GAL4/DNA-binding domain (DBD) or VP16 were constructed using pcDNA5/GAL4 and pcDNA5/VP16, respectively. A segment of the receptor interaction domain (RID) of SRC1 (Leo et al 2000) ) (SRC1/RID, 569-781) was cloned into pcDNA5-GAL4/DBD. The expression plasmids for hCAR/ligand binding domain (LBD) fused with GAL4/DNA-binding domain (DBD) was described previously (Kanno et al., 2010) . The preparation of the XREM-driven luciferase reporter plasmid (XREM-luc) has been described elsewhere (Kanno et al., 2010) .
The genes encoding the full-length human SRC1, SRC2, peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC1), and protein arginine methyltransferase 1 This article has not been copyedited and formatted. The final version may differ from this version. 
Cell culture
The stable hPXR-expressing HepG2 cell line (Hep-hPXR) was established by pCMV3tag6-hPXR transfection, followed by serial hygromycin selections. HepG2 and Hep-hPXR cells were cultured in Dulbecco's modified Eagle's medium (Wako, Osaka, Japan) containing 10% fetal bovine serum and penicillin-streptomycin in a humidified atmosphere of 5% CO 2 at 37°C.
Luciferase reporter analysis
Using PEI Max reagent (Polysciences Inc., Warrington, PA.), cells were transfected with the appropriate expression and reporter plasmids, as well as pGL4.74 (hRluc/TK; Promega, Madison, WI) as an internal standard. After overnight incubation, the cells were treated with individual test compounds for 24 h. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). The firefly luciferase activities were normalized against those of Renilla luciferase.
Quantitative reverse-transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from whole cell lysates using ISOGEN II (Nippon Gene Co. ., Toyama, 
Mammalian 2-hybrid assay
HepG2 cells were transfected with the pG5luc reporter plasmid, pGL4.74 and expression vectors for VP16-hPXR/LBD and GAL4-SRC1/RID using the PEI Max reagent. On the following day, the cells were treated with NigC or solvent (0.1% DMSO) for 24 h. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System.
Western blot analysis
HepG2 cells were harvested and lysed in SDS sample buffer. The whole-cell lysates were resolved by SDS-PAGE and immunoblotting was performed using anti-CYP3A4 (1:1000 dilution; Cell Signaling Technology Inc., Beverly, MA) and anti-Tubulin (1:20000 dilution; MBL, Nagoya, Japan) as primary antibodies. A horseradish peroxidase-conjugated anti-rabbit IgG intensity was analyzed using Image Quant Software (Molecular Dynamics, Sunnyvale, CA).
Human primary hepatocytes and treatment
Human primary hepatocytes (HPHs) (HPH#1, Male, BIOPREDIC International, Rennes, France; HPH#2, Female, In Vitro ADMET Laboratories, Inc., Columbia, MD, USA) were plated and cultured according to the manufacturers' protocols. Cells were treated with each compound for 24 h. The mRNA expression level was measured by the above-mentioned qRT-PCR.
Statistical analysis
Statistically significant differences were determined using one-way analysis of variance followed by Tukey's multiple comparison test as the post hoc test, and differences were considered statistically significant at P < 0.05. by the mammalian 1-hybrid assay using GAL4-hPXR/LBD and pG5-luc in HepG2 cells, the cyclohexene-type amide alkaloid, nigramide C (NigC), showed potent activation of hPXR.
NigC belongs to a class of dimeric amide alkaloids possessing a cyclohexene ring (Fig. 1) . To clarify the structure-activity relationship as an agonist of hPXR, the effects of some structurally related compounds on the hPXR-dependent transcription were evaluated. HepG2 cells transfected with GAL4-hPXR/LBD and pG5luc were treated with individual test compounds at either 10 μ M ( Fig. 2A ) or 1 μ M (Fig. 2B) . NigC (1) showed the most potent activity, followed by compounds 2 and NigJ (3). However, two biosynthetic precursors of the nigramide compounds, ilepcimide (10) and piperine (11), did not show a statistically significant effect.
Nigramide C is an agonist of PXR but not CAR
To verify the effect of NigC on the hPXR-dependent transactivation of a reporter gene, HepG2 (Fig. 3B ). This activation was more efficient than the positive control (10 μ M Rif). To test whether NigC affects hCAR-dependent transcriptional activation, we conducted the luciferase reporter assay using GAL4-hCAR/LBD.
NigC at concentrations of up to 10 μ M had no effect on the basal transactivity of hCAR (supplemental figure and our previously report, Kanno et al., 2014) . Furthermore, we investigated whether NigC could reverse inverse agonist-mediated suppression. Although PK11195-suppressed transactivity of CAR was reversed by CITCO, CAR agonist, CAR activity was not affected by NigC (Fig.3C) . These results suggest that NigC is not inverse agonist and agonist of CAR. (Fig. 4A) .
Nigramide C enhances the interaction between PXR and co-activators
Furthermore, to see whether NigC promotes direct protein-protein interaction between the co-activators and hPXR, a mammalian 2-hybrid assay was carried out in HepG2 cells transfected with pG5luc, VP16-hPXR/LBD, or VP16, and GAL4-SRC1/RID. The interaction of hPXR with SRC1/RID was enhanced by NigC to a similar level as that by Rif (Fig. 4B ).
Nigramide C induces CYP3A4 mRNA and protein expression in HepG2-derived cells stably overexpressing PXR (HepG2-hPXR) and in human primary hepatocytes
We examined whether NigC could induce the expression of endogenous CYP3A4 mRNA and 
Discussion
PXR is a key regulator of drug metabolism in response to xenobiotics. Among compound 1 (NigC) and its structurally related compounds (Fig. 1) , the most effective hPXR agonist activity was observed by NigC, which was followed by compounds 2 and 3 (NigJ) (Fig. 2) . The 3,4-methylenedioxyphenyl moiety at C-1 seems to be a requisite for potent agonist activity with insertion of an olefin group greatly decreasing the activity (1 vs. 6 and 2 vs. 7). Compared with the aliphatic chain, the 3,4-methylenedioxyphenyl moiety is preferable for the agonist activity, which is evidenced by comparing compounds 1 and 3 (Fig. 2B) . Altering the olefin position in the cyclohexene ring may contribute to the PXR agonist activity, which is demonstrated by comparing compounds 1 and 2 (Fig. 2B) , and 6 and 7 (Fig. 2A) .
The spiciness of black pepper is mainly caused by piperine (11) and structurally related compounds. While these compounds function as insecticides in the original plant (Siddiqui et al., 2005) , in mammalian systems they function as inhibitors of various xenobiotic metabolizing enzymes such as CYP3A4 and transporters represented by ATP-binding cassette sub-family B member 1 (ABCB1; also known as P-glycoprotein or MDR1) upon acute exposure. Although up-regulation of PXR target genes, such as CYP3A4 and MDR1, was observed after long-term exposure to 11 (Wang et al., 2013) , we did not observe a significant activation of hPXR by the monomer-type compounds 10 and 11 ( Fig. 2A) .
NigC markedly enhanced the luciferase reporter activity measured using GAL4-hPXR/LBD in HepG2 cells (Fig. 3A) . Furthermore, NigC induced the XREM-luc reporter activity in hPXR-transfected HepG2 cells (Fig. 3B ). These observations suggest that NigC transactivates the XREM-enhancer of CYP3A4 via interaction with hPXR/LBD to a similar extent as does Rif, a well-known agonist of hPXR (Goodwin et al., 1999; Bertilsson et al., 1998) . Generally, agonist binding causes conformational changes in the LBD of nuclear receptors, leading to recruitment of co-activators in place of co-repressors. We demonstrated that overexpression of known PXR co-activators enhanced NigC-mediated hPXR transactivation (Fig. 4A) . Additionally, our results obtained by a mammalian 2-hybrid assay demonstrated that NigC-mediated hPXR activation enhanced the recruitment of SRC1 (Fig.   4B ).
In most cases, agonists of hPXR are known to act as ligands of hCAR. For example, clotrimazole, T0901317, and PK11195 are not only agonists of hPXR but also inverse agonists of hCAR (Moore et al., 2000; Li et al., 2008; Kanno et al., 2013 ). In the current study, the basal transcriptional activity of ligand-free hCAR was not affected by NigC at concentrations of up to 10 μ M, although a little but significant suppression was observed at 25 μ M (Fig. 3C and supplemental Figure) . In contrast, the basal activity of hCAR was significantly suppressed in the presence of 10 μ M PK11195. These observations indicate that NigC is not ligand of hCAR. It is notable that compound 3 (NigJ) , which differ its structure from 1 by only C-6 aliphatic moiety, have been identified as a potent inverse agonist of hCAR (Kanno et al., CYP3A4 plays a major role in the metabolism of a wide range of clinically used pharmaceutical drugs and xenobiotics. Because PXR is the dominant activator of CYP3A4 transcription, we further investigated whether NigC could induce CYP3A4 expression.
Although NigC increased the expression of endogenous CYP3A4 mRNA in Hep-hPXR cells and was as potent as Rif (Fig. 5) , only a modest induction was observed in human primary hepatocytes compared with Rif (Fig. 6) . The difference in the induction level of the endogenous gene by NigC between Hep-hPXR cells and human primary hepatocytes remains to be solved in future studies. However, it is possible that this difference stems from different metabolic stability of NigC in different cell types, as in the case of buprenorphine, which showed potent induction of CYP3A4 in PXR-transfected HepG2 cells but not in human primary hepatocytes, because of different metabolic stabilities (Li et al., 2010) . Taking account of the contents of NigC in the roots of P. nigrum (0.0015%) (Wei et al. 2004b) , the intake amount of NigC by human would be very low (<0.5 mg/day). But the interaction of NigC and other drugs would be taken into consideration when it was used at a high concentration. lysates were separated by SDS-PAGE, and proteins were detected by immunoblotting using antibodies against CYP3A4 and tubulin, which was used as a loading control. 
